571 related articles for article (PubMed ID: 15604287)
1. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
2. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
3. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
4. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
5. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
7. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
[TBL] [Abstract][Full Text] [Related]
8. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
10. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
12. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
14. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
15. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
[TBL] [Abstract][Full Text] [Related]
17. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski W; Gibo DM; Hulet SW; Connor JR; Gillespie GY
Clin Cancer Res; 1999 May; 5(5):985-90. PubMed ID: 10353730
[TBL] [Abstract][Full Text] [Related]
18. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
19. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
20. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]